/, Recombinant Mouse Cytokines/Mouse Interleukin-13 Recombinant

Mouse Interleukin-13 Recombinant

Categories:

$70.00$4,700.00

SKU: RKP20109 Tags: , , ,

Description

Accession
P20109
Source
Optimized DNA sequence encodingMouse Interleukin-13 mature chain was expressed in Escherichia Coli.
Molecular weight
Native Mouse IL-13, generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately12 kDa. Recombinant IL-13 is a monomer protein consisting of111 amino acid residue subunits,and migrates as an approximately kDa protein under non-reducingand reducing conditions in SDS-PAGE.
Purity
>95%, as determined by SDS-PAGE and HPLC
Biological Activity
The ED(50) was determined by the dose-dependent proliferation of TF-1 cells was ≤.0 ng/ml, corresponding to a specific activity of ≥ x units/mg.
Protein Sequence
MALWVTAVLA LACLGGLAAP GPVPRSVSLP LTLKELIEEL SNITQDQTPL CNGSMVWSVD LAAGGFCVAL DSLTNISNCN AIYRTQRILH GLCNRKAPTT VSSLPDTKIE VAHFITKLLS YTKQLFRHGP F
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation
Recombinant mouse IL-13 was lyophilized from a.2 μm filtered PBS solution.
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Molecular function

Methods

Decreased expression of MHCII in antigen presenting cells from the lungs of IL-19-/- mice.

  • Ag, shaded symbols) and from naïve animals that were challenged with LPS (B, at 1 or 5 µg/dose as indicated, shaded symbols) or IL-13 (C-E, shaded symbols).

Antibodies and proteins

  • Antibodies directed against IκBα (#4814), phospho p38 (#9211), p38 (#9212), phospho ERK1/2 (#9106), ERK1/2 (#9102), phospho JNK1/2 (#9251), JNK1/2 (#9252) and phospho c-Jun (#3270) were all from Cell Signaling Technology.
  • Wnt5a antibody was from Biotechnology (Sc-30224), NFATC2 for Western blotting was from and for immunofluorescence from (Sc-13034), and the mouse monoclonal β-actin from .
  • LPS (from E.
  • Recombinant IL-4 and IL-13 proteins were bought from .
  • HlyA was obtained from Prof. S. Bhakdi (Mainz University, Germany).
  • HlyA was preincubated with polymyxin B (50 µg/ml) at 4°C for 30 min to remove any possible LPS contamination.
  • Induction of Alternatively Activated RAW Macrophages by Th2 Cytokines: The RAW264.7 cell line (1×105) was treated with a combination of 10 ng/mL each of IL-4, IL-10, and IL-13 for 72 h, with the cytokine mixture added every 24 h. The resulting cells were macrophages in alternative activation state, named as IL-treated RAW macrophages.

CAT-354 decreases AHR and eosinophilia in a cynomolgus model of antigen challenge.

  • Data displayed as the arithmetic mean ± SEM of individual animal changes at day 11 compared with day 1 for the phase I and II changes, respectively and phase II compared with phase I in the endpoint column.

Percentage of goblet and ciliated cells in PBEC(N) and (A) cultures.

  • Numbers of ciliated cells expressed as a percentage of total on day 28 for PBEC stimulated with IL-9, IL-9/IL-13 combination and IL-13.

Animals

  • C57BL/6J mice were obtained from the .
  • Ikbkb floxed mice (
Stay in the loop
For new product information and regular updates on our product range please fill your details
Loading